SI4116301T1 - Kondenzirana triciklična spojina in njena medicinska uporaba - Google Patents
Kondenzirana triciklična spojina in njena medicinska uporabaInfo
- Publication number
- SI4116301T1 SI4116301T1 SI202130359T SI202130359T SI4116301T1 SI 4116301 T1 SI4116301 T1 SI 4116301T1 SI 202130359 T SI202130359 T SI 202130359T SI 202130359 T SI202130359 T SI 202130359T SI 4116301 T1 SI4116301 T1 SI 4116301T1
- Authority
- SI
- Slovenia
- Prior art keywords
- medical use
- tricyclic compound
- condensed tricyclic
- condensed
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11002—[Pyruvate dehydrogenase (acetyl-transferring)] kinase (2.7.11.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020036931 | 2020-03-04 | ||
| JP2021001452 | 2021-01-07 | ||
| PCT/JP2021/008055 WO2021177330A1 (ja) | 2020-03-04 | 2021-03-03 | 縮合三環性化合物及びその医薬用途 |
| EP21764169.5A EP4116301B1 (en) | 2020-03-04 | 2021-03-03 | Fused tricyclic compound and medicinal use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI4116301T1 true SI4116301T1 (sl) | 2025-12-31 |
Family
ID=77613417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202130359T SI4116301T1 (sl) | 2020-03-04 | 2021-03-03 | Kondenzirana triciklična spojina in njena medicinska uporaba |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20230025880A1 (https=) |
| EP (2) | EP4116301B1 (https=) |
| JP (2) | JP7739012B2 (https=) |
| KR (1) | KR20220149688A (https=) |
| CN (1) | CN115151543B (https=) |
| AU (1) | AU2021230880A1 (https=) |
| BR (1) | BR112022014749A2 (https=) |
| CA (1) | CA3166747A1 (https=) |
| CL (1) | CL2022002355A1 (https=) |
| CO (1) | CO2022012548A2 (https=) |
| DK (1) | DK4116301T3 (https=) |
| ES (1) | ES3052010T3 (https=) |
| FI (1) | FI4116301T3 (https=) |
| HR (1) | HRP20251364T1 (https=) |
| IL (1) | IL295836B2 (https=) |
| LT (1) | LT4116301T (https=) |
| MX (1) | MX2022010950A (https=) |
| PE (1) | PE20221908A1 (https=) |
| PH (1) | PH12022552259A1 (https=) |
| PL (1) | PL4116301T3 (https=) |
| PT (1) | PT4116301T (https=) |
| RS (1) | RS67408B1 (https=) |
| SI (1) | SI4116301T1 (https=) |
| SM (1) | SMT202500464T1 (https=) |
| TW (1) | TWI884224B (https=) |
| WO (1) | WO2021177330A1 (https=) |
| ZA (1) | ZA202209620B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10800784B2 (en) * | 2018-02-01 | 2020-10-13 | Japan Tobacco Inc. | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof |
| PL4116301T3 (pl) * | 2020-03-04 | 2026-02-16 | Japan Tobacco Inc. | Skondensowany związek tricykliczny i jego zastosowanie medyczne |
| CN117897382A (zh) * | 2021-09-01 | 2024-04-16 | 日本烟草产业株式会社 | 含氮三环化合物及其药物用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004025220D1 (de) * | 2003-04-11 | 2010-03-11 | High Point Pharmaceuticals Llc | Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| KR100808551B1 (ko) * | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| MY182884A (en) * | 2013-03-15 | 2021-02-05 | Japan Tobacco Inc | Pyrazole-amide compound and medicinal uses therefor |
| CA2994027C (en) * | 2015-07-31 | 2023-10-10 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| US10800784B2 (en) * | 2018-02-01 | 2020-10-13 | Japan Tobacco Inc. | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof |
| US20220362215A1 (en) | 2018-09-11 | 2022-11-17 | Japan Tobacco Inc. | Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound |
| PL4116301T3 (pl) | 2020-03-04 | 2026-02-16 | Japan Tobacco Inc. | Skondensowany związek tricykliczny i jego zastosowanie medyczne |
-
2021
- 2021-03-03 PL PL21764169.5T patent/PL4116301T3/pl unknown
- 2021-03-03 US US17/602,103 patent/US20230025880A1/en active Pending
- 2021-03-03 PE PE2022001891A patent/PE20221908A1/es unknown
- 2021-03-03 MX MX2022010950A patent/MX2022010950A/es unknown
- 2021-03-03 EP EP21764169.5A patent/EP4116301B1/en active Active
- 2021-03-03 WO PCT/JP2021/008055 patent/WO2021177330A1/ja not_active Ceased
- 2021-03-03 JP JP2021033150A patent/JP7739012B2/ja active Active
- 2021-03-03 IL IL295836A patent/IL295836B2/en unknown
- 2021-03-03 EP EP25206111.4A patent/EP4663189A3/en active Pending
- 2021-03-03 FI FIEP21764169.5T patent/FI4116301T3/fi active
- 2021-03-03 DK DK21764169.5T patent/DK4116301T3/da active
- 2021-03-03 PT PT217641695T patent/PT4116301T/pt unknown
- 2021-03-03 KR KR1020227032125A patent/KR20220149688A/ko active Pending
- 2021-03-03 SM SM20250464T patent/SMT202500464T1/it unknown
- 2021-03-03 AU AU2021230880A patent/AU2021230880A1/en active Pending
- 2021-03-03 ES ES21764169T patent/ES3052010T3/es active Active
- 2021-03-03 RS RS20251131A patent/RS67408B1/sr unknown
- 2021-03-03 PH PH1/2022/552259A patent/PH12022552259A1/en unknown
- 2021-03-03 CA CA3166747A patent/CA3166747A1/en active Pending
- 2021-03-03 CN CN202180018517.1A patent/CN115151543B/zh active Active
- 2021-03-03 LT LTEPPCT/JP2021/008055T patent/LT4116301T/lt unknown
- 2021-03-03 TW TW110107548A patent/TWI884224B/zh active
- 2021-03-03 SI SI202130359T patent/SI4116301T1/sl unknown
- 2021-03-03 BR BR112022014749A patent/BR112022014749A2/pt unknown
- 2021-03-03 HR HRP20251364TT patent/HRP20251364T1/hr unknown
-
2022
- 2022-08-29 CL CL2022002355A patent/CL2022002355A1/es unknown
- 2022-08-29 ZA ZA2022/09620A patent/ZA202209620B/en unknown
- 2022-09-01 CO CONC2022/0012548A patent/CO2022012548A2/es unknown
-
2025
- 2025-09-03 JP JP2025145992A patent/JP2025175000A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125556T1 (el) | Γεφυρωμενες τρικυκλικες καρβαμοϋλπυριδονης ενωσεις και φαρμακευτικη χρηση αυτωn | |
| IL289975A (en) | Use of cannabidiol in the treatment of dravet syndrome | |
| SI4116301T1 (sl) | Kondenzirana triciklična spojina in njena medicinska uporaba | |
| IL277640A (en) | Humanized bcma antibody and bcma-car-t cells | |
| SI3661954T1 (sl) | Muteini interlevkina-21 in postopki zdravljenja | |
| SI3252053T1 (sl) | Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje okužb s HIV | |
| IL290256A (en) | Anti-pd-1 antibody and pharmaceutical use thereof | |
| CL2015001702A1 (es) | Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. | |
| BR112016020199A2 (pt) | Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| DK4014976T3 (da) | Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan | |
| CL2008001038A1 (es) | Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano | |
| AR097500A1 (es) | Métodos de diagnóstico y composiciones para el tratamiento de glioblastoma | |
| BR112013014189A2 (pt) | composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções | |
| DK3409672T3 (da) | Parazolderivater med kondenseret ring og fremstillingsfremgangsmåde dertil og anvendelse deraf i behandling af kræftformer, inflammation og immunsygdomme | |
| EP3352781A4 (en) | 4 'SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | |
| EP4355749A4 (en) | TRICYCLIC PARP1 INHIBITORS AND THEIR USES | |
| IL284907A (en) | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor | |
| IL311331A (en) | Pharmaceutical composition and use thereof | |
| EP2958580A4 (en) | INHIBITION OF SEMA3A FOR THE PREVENTION AND TREATMENT OF OCCULAR HYPERPERMEABILITY | |
| EP3424475A4 (en) | ABSORBING BODY AND HYGIENE ITEMS | |
| CL2013001250A1 (es) | Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion. | |
| IL271223A (en) | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use | |
| DK2956471T3 (da) | Il-1beta-hæmmersammensætning og anvendelse deraf | |
| IL283899A (en) | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer | |
| EP4165042A4 (en) | TRICYCLIC PSYCHOPLASTOGENS AND THEIR USES |